Iranian Journal of Pathology

Histopathological Evaluation of PYGO2 Expression in Esophageal Squamous Cell Carcinoma

Document Type : Original Research

Authors

Sima Ardalan khales 1
Habibeh Rahmani kalat 2
Sedigheh Soleymani 2
Amir Hossein Jafarian 3
Mohammad Mahdi Forghanifard 2

1 Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran

3 Department of Pathology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

https://doi.org/10.30699/ijp.2024.2024609.3269
Abstract
Background & Objective: Esophageal squamous cell carcinoma (ESCC) is one of the world's deadliest cancer diseases. Deregulation of developmental signaling pathways such as Wnt/β-catenin is frequently implicated in a wide range of human cancers. The present study was designed to analyze the expression of the Pygopus2 (PYGO2) protein, the main co-activator of the Wnt/β-catenin signaling pathway, in ESCC tissues and evaluate its probable correlation with clinicopathological features of patients.
Methods: In this study, PYGO2 protein expression was assessed in tumors and margin normal tissues from 50 ESCC patients using immunohistochemical analysis, and its clinicopathological relevance in the patients was evaluated.  
Results: A significant PYGO2 overexpression was observed in %32 of the tumor cells. Interestingly, PYGO2 expression was significantly correlated with the depth of tumor invasion (P= 0.021).
Conclusion: PYGO2 protein may be highly expressed in ESCC in correlation with the invasiveness of the disease. Therefore, it may be used as a biomarker for the diagnosis of invasive ESCC and a putative therapeutic target to inhibit ESCC invasiveness.

Keywords

Esophageal squamous cell carcinoma
Immunohistochemistry
PYGO2
Wnt/β-catenin signaling pathway

Subjects

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [DOI:10.3322/caac.21660] [PMID]
  2. Mao WM, Zheng WH, Ling ZQ. Epidemiologic risk factors for esophageal cancer development. Asian Pac J Cancer Prev. 2011;12(10):2461-6.
  3. Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007;10(1):70-82.
  4. Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112-20. [DOI:10.4251/wjgo.v6.i5.112] [PMID] [[PMCID]
  5. Sheng Y, Liu K, Wu Q, Oi N, Chen H, Reddy K, et al. PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenografts. Oncotarget. 2016;7(21):30977-89. [DOI:10.18632/oncotarget.9050] [PMID] [[PMCID]
  6. Miller TC, Mieszczanek J, Sánchez-Barrena MJ, Rutherford TJ, Fiedler M, Bienz M. Evolutionary adaptation of the Fly Pygo PHD finger toward recognizing histone H3 tail methylated at Arginine 2. Structure. 2013;21(12):2208-20. [DOI:10.1016/j.str.2013.09.013] [PMID] [[PMCID]
  7. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9-26.[PMID] [[PMCID] [DOI:10.1016/j.devcel.2009.06.016]
  8. Wang Z, Zhao T, Zhang S, Wang J, Chen Y, Zhao H, et al. The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy. Biomark Res. 2021;9(1):68. [DOI:10.1186/s40364-021-00323-7] [PMID] [[PMCID]
  9. Liu Y, Dong QZ, Wang S, Fang CQ, Miao Y, Wang L, et al. Abnormal expression of Pygopus 2 correlates with a malignant phenotype in human lung cancer. BMC Cancer. 2013;13(1):346. [DOI:10.1186/1471-2407-13-346] [PMID] [[PMCID]
  10. Ling J, Tang Z, Yang W, Li Y, Dong X. Pygo2 activates BRPF1 via Pygo2-H3K4me2/3 interaction to maintain malignant progression in colon cancer. Exp Cell Res. 2023;431(1):113696. [DOI:10.1016/j.yexcr.2023.113696] [PMID]
  11. Bodnar L, Stanczak A, Cierniak S, Smoter M, Cichowicz M, Kozlowski W, et al. Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. Journal of ovarian research. 2014;7(1):1-10. [DOI:10.1186/1757-2215-7-16] [PMID] [[PMCID]
  12. Liu R, Qin X, Ji C, Zeng W, Yang Y, Tan W. Pygopus 2 promotes kidney cancer OS-RC-2 cells proliferation and invasion in vitro and in vivo. Asian J Urol. 2015;2(3):151-7. [DOI:10.1016/j.ajur.2015.06.009] [PMID] [[PMCID]
  13. Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020;19(1):165.[[PMCID] [DOI:10.1186/s12943-020-01276-5] [PMID]
  14. Cochran WG. Sampling techniques: john wiley & sons; 1977.
  15. Wittekind C, Brierley JD, Lee A, van Eycken E. TNM supplement: a commentary on uniform use: John Wiley & Sons; 2019. [DOI:10.1002/9781119263975]
  16. Ghodsi M, Jafarian AH, Montazer M, Sadeghian MH, Forghanifard MM. Diagnostic clinical relevance of developmental pluripotency-associated 2 (DPPA2) in colorectal cancer. Int J Surg. 2015;13:193-7. [DOI:10.1016/j.ijsu.2014.11.036] [PMID]
  17. Andrews PG, Lake BB, Popadiuk C, Kao KR. Requirement of Pygopus 2 in breast cancer. Int J Oncol. 2007;30(2):357-63.
  18. Htun MW, Shibata Y, Soe K, Koji T. Nuclear Expression of Pygo2 Correlates with Poorly Differentiated State Involving c-Myc, PCNA and Bcl9 in Myanmar Hepatocellular Carcinoma. Acta Histochem Cytochem. 2021;54(6):195-206. [DOI:10.1267/ahc.21-00090] [PMID] [[PMCID]
  19. Lu X, Pan X, Wu C-J, Zhao D, Feng S, Zang Y, et al. An in vivo screen identifies PYGO2 as a driver for metastatic prostate cancer. Cancer research. 2018; 78(14):3823-33. [PMID] [[PMCID] [DOI:10.1158/0008-5472.CAN-17-3564]
  20. Zhang D, Liu Y, Wu Q, Zheng Y, Kaweme NM, Zhang Z, et al. Pygo2 as a novel biomarker in gastric cancer for monitoring drug resistance by upregulating MDR1. Journal of Cancer. 2021;12(10):2952. [DOI:10.7150/jca.53356] [PMID] [[PMCID]
  21. Wang ZX, Chen YY, Li BA, Tan GW, Liu XY, Shen SH, et al. Decreased pygopus 2 expression suppresses glioblastoma U251 cell growth. J Neurooncol. 2010; 100(1):31-41. [DOI:10.1007/s11060-010-0144-6] [PMID]
  22. Chi Y, Wang F, Zhang T, Xu H, Zhang Y, Shan Z, et al. miR-516a-3p inhibits breast cancer cell growth and EMT by blocking the Pygo2/Wnt signalling pathway. J Cell Mol Med. 2019;23(9):6295-307. [DOI:10.1111/jcmm.14515] [PMID] [[PMCID]
  23. Talla SB, Brembeck FH. The role of Pygo2 for Wnt/ss-catenin signaling activity during intestinal tumor initiation and progression. Oncotarget. 2016;7(49): 80612-32. [DOI:10.18632/oncotarget.13016] [PMID] [[PMCID]
  24. Popadiuk CM, Xiong J, Wells MG, Andrews PG, Dankwa K, Hirasawa K, et al. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clin Cancer Res. 2006;12(7 Pt 1):2216-23. [DOI:10.1158/1078-0432.CCR-05-2433] [PMID]
  25. Moghbeli M, Abbaszadegan MR, Farshchian M, Montazer M, Raeisossadati R, Abdollahi A, et al. Association of PYGO2 and EGFR in esophageal squamous cell carcinoma. Med Oncol. 2013;30(2):516. [DOI:10.1007/s12032-013-0516-9] [PMID]
Iranian Journal of Pathology
Volume 19, Issue 4
Autumn 2024
Pages 415-421

  • Receive Date 10 March 2024
  • Revise Date 17 May 2024
  • Accept Date 22 June 2024

Home

Guide for Authors

Submit Manuscript

Contact Us